Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 7/20 | 0.50 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081017 | 0.88 | GPR35 (0.39) | ALOX5P2RX3PPARGPPARARNASEH1 | |
| SCHEMBL6080422 | 0.88 | KDM4E (0.43) | ALOX5KDM4EGAA | |
| SCHEMBL6079763 | 0.84 | PPARA (0.49) | ALOX5PPARGPPARA | |
| SCHEMBL6080252 | 0.83 | P2RX3 (0.45) | ALOX5P2RX3RNASEH1KDM4E | |
| SCHEMBL6081306 | 0.82 | PDE10A (0.45) | KDM4EPDE10AGPR35ALOX15 | |
| SCHEMBL6080506 | 0.81 | P2RX3 (0.43) | P2RX3CRHBPCRHR2RNASEH1KDM4E | |
| SCHEMBL6080302 | 0.80 | GPR35 (0.44) | RNASEH1KDM4EPDE10AGPR35ALOX15 | |
| SCHEMBL6080886 | 0.80 | MAPT (0.44) | RNASEH1MAPT | |
| SCHEMBL6080942 | 0.79 | HAO1 (0.39) | KDM4EPDE10AGAAMAPTGPR35 | |
| SCHEMBL6081161 | 0.79 | PIM1 (0.41) | KDM4EGAAGPR35ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | ALOX5 1447/4885P2RX3 465/4885CRHBP 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.